367 related articles for article (PubMed ID: 28955032)
1. Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model.
Jespersen H; Lindberg MF; Donia M; Söderberg EMV; Andersen R; Keller U; Ny L; Svane IM; Nilsson LM; Nilsson JA
Nat Commun; 2017 Sep; 8(1):707. PubMed ID: 28955032
[TBL] [Abstract][Full Text] [Related]
2. HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice.
Forsberg EMV; Lindberg MF; Jespersen H; Alsén S; Bagge RO; Donia M; Svane IM; Nilsson O; Ny L; Nilsson LM; Nilsson JA
Cancer Res; 2019 Mar; 79(5):899-904. PubMed ID: 30622115
[TBL] [Abstract][Full Text] [Related]
3. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.
Nguyen LT; Saibil SD; Sotov V; Le MX; Khoja L; Ghazarian D; Bonilla L; Majeed H; Hogg D; Joshua AM; Crump M; Franke N; Spreafico A; Hansen A; Al-Habeeb A; Leong W; Easson A; Reedijk M; Goldstein DP; McCready D; Yasufuku K; Waddell T; Cypel M; Pierre A; Zhang B; Boross-Harmer S; Cipollone J; Nelles M; Scheid E; Fyrsta M; Lo CS; Nie J; Yam JY; Yen PH; Gray D; Motta V; Elford AR; DeLuca S; Wang L; Effendi S; Ellenchery R; Hirano N; Ohashi PS; Butler MO
Cancer Immunol Immunother; 2019 May; 68(5):773-785. PubMed ID: 30747243
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.
Dafni U; Michielin O; Lluesma SM; Tsourti Z; Polydoropoulou V; Karlis D; Besser MJ; Haanen J; Svane IM; Ohashi PS; Kammula US; Orcurto A; Zimmermann S; Trueb L; Klebanoff CA; Lotze MT; Kandalaft LE; Coukos G
Ann Oncol; 2019 Dec; 30(12):1902-1913. PubMed ID: 31566658
[TBL] [Abstract][Full Text] [Related]
5. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma.
Aarntzen EH; Bol K; Schreibelt G; Jacobs JF; Lesterhuis WJ; Van Rossum MM; Adema GJ; Figdor CG; Punt CJ; De Vries IJ
Cancer Res; 2012 Dec; 72(23):6102-10. PubMed ID: 23010076
[TBL] [Abstract][Full Text] [Related]
6. Exogenous human herpesvirus 6 reinfection after tumor-infiltrating T-lymphocyte therapy.
Filippova A; Charles J; Epaulard O; Germi R; Persoons V; Templier I; Leccia MT; Dreno B; Malova I; Morand P; Lupo J
Cytotherapy; 2018 Apr; 20(4):521-523. PubMed ID: 29434005
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases.
Mehta GU; Malekzadeh P; Shelton T; White DE; Butman JA; Yang JC; Kammula US; Goff SL; Rosenberg SA; Sherry RM
J Immunother; 2018 Jun; 41(5):241-247. PubMed ID: 29672342
[TBL] [Abstract][Full Text] [Related]
8. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma.
Rosenberg SA; Yang JC; Robbins PF; Wunderlich JR; Hwu P; Sherry RM; Schwartzentruber DJ; Topalian SL; Restifo NP; Filie A; Chang R; Dudley ME
J Immunother; 2003; 26(5):385-93. PubMed ID: 12973027
[TBL] [Abstract][Full Text] [Related]
9. Adoptive T-cell transfer in melanoma.
Itzhaki O; Levy D; Zikich D; Treves AJ; Markel G; Schachter J; Besser MJ
Immunotherapy; 2013 Jan; 5(1):79-90. PubMed ID: 23256800
[TBL] [Abstract][Full Text] [Related]
10. Is antigen specificity the key to efficient adoptive T-cell therapy?
Labarriere N; Khammari A; Lang F; Dreno B
Immunotherapy; 2011 Apr; 3(4):495-505. PubMed ID: 21463191
[TBL] [Abstract][Full Text] [Related]
11. IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanoma.
Melief SM; Visser M; van der Burg SH; Verdegaal EME
Cancer Immunol Immunother; 2017 Jul; 66(7):913-926. PubMed ID: 28401257
[TBL] [Abstract][Full Text] [Related]
12. Predictors of tumor-infiltrating lymphocyte efficacy in melanoma.
Zikich D; Schachter J; Besser MJ
Immunotherapy; 2016; 8(1):35-43. PubMed ID: 26653685
[TBL] [Abstract][Full Text] [Related]
13. Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma.
Foley KC; Nishimura MI; Moore TV
Melanoma Res; 2018 Jun; 28(3):171-184. PubMed ID: 29521881
[TBL] [Abstract][Full Text] [Related]
14. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
Weber J; Atkins M; Hwu P; Radvanyi L; Sznol M; Yee C;
Clin Cancer Res; 2011 Apr; 17(7):1664-73. PubMed ID: 21325070
[TBL] [Abstract][Full Text] [Related]
15. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.
Mahvi DA; Meyers JV; Tatar AJ; Contreras A; Suresh M; Leverson GE; Sen S; Cho CS
J Immunother; 2015; 38(2):54-61. PubMed ID: 25658614
[TBL] [Abstract][Full Text] [Related]
16. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
17. [Principles of adoptive cell therapy based on "Tumor Infiltrating Lymphocytes"].
Martins F; Orcurto A; Michielin O; Coukos G
Rev Med Suisse; 2016 May; 12(519):989-93. PubMed ID: 27424426
[TBL] [Abstract][Full Text] [Related]
18. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
[TBL] [Abstract][Full Text] [Related]
19. The adoptive transfer of cultured T cells for patients with metastatic melanoma.
Yang JC
Clin Dermatol; 2013; 31(2):209-19. PubMed ID: 23438384
[TBL] [Abstract][Full Text] [Related]
20. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.
Dudley ME; Yang JC; Sherry R; Hughes MS; Royal R; Kammula U; Robbins PF; Huang J; Citrin DE; Leitman SF; Wunderlich J; Restifo NP; Thomasian A; Downey SG; Smith FO; Klapper J; Morton K; Laurencot C; White DE; Rosenberg SA
J Clin Oncol; 2008 Nov; 26(32):5233-9. PubMed ID: 18809613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
